Vitamin D3 for people with bronchiectasis and low vitamin D

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-CF bronchiectasis who took part in the earlier study UW 22-317. People with low vitamin D get vitamin D3; people with normal vitamin D get no drug.

Age

18 years or above

Sex

Male or female

Disease stage

Non-CF bronchiectasis (widened airways not caused by cystic fibrosis), confirmed by a high-resolution CT (HRCT) scan.

Earlier treatment

People who already take vitamin D supplements cannot join. Participants must have taken part in the prior study UW 22-317.

Biomarker or test result

Blood 25-hydroxyvitamin-D level is checked. People with vitamin D deficiency get vitamin D3, aiming for a level of 50 nmol/L or above.

Main reasons for not taking part

• Asthma, COPD or other lung diseases at the same time
• Osteoporosis (weak bones)
• Already taking vitamin D supplements
• Advanced chronic kidney disease with eGFR < 30mL/min

The registry criteria, word for word

What the trial wants to find out

This study seeks to address the limitations in previous related studies on vitamin D replacement and bronchiectasis exacerbation occurrence through a self-controlled pilot study. The investigators aim to investigate whether vitamin D replacement in bronchiectasis patients with vitamin D deficiency can reduce hospitalized bronchiectasis exacerbation occurrence. Patients who participated in the prior study entitled "Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation" (UW 22-317) will be invited for participation during regular clinic follow-up and management in Queen Mary Hospital. If participants are willing to join the further research, participants will be recruited in this self-controlled study. There are some differences from usual management to non-CF bronchiectasis subjects. The study subjects would be checked for their blood 25-hydroxyvitamin-D level during the study period. The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU (if needed). The investigators aim to correct their Vitamin D deficiency completely, aiming at blood 25-hydroxyvitamin-D level >=50, i.e. treat to target. The dose depends on the level of Vitamin D after replacement. If blood 25-hydroxyvitamin-D level is 50 or above, then 1000 IU is suffice. If blood 25-hydroxyvitamin-D level is still below 50, the investigators will increase to 2000 IU.

The 2 groups in the trial

• Vitamin D replacementExisting treatment, for comparison

  Those with vitamin D deficiency will be replaced with vitamin D3 at 1000 IU at the first visit. Vitamin D3 1000 IU is expected to increase blood 25-hydroxyvitamin-D level by 25 nmol/L. Blood 25-hydroxyvitamin-D level will be rechecked 3 months after replacement. If the blood 25-hydroxyvitamin-D level is still below 50 nmol/L, the vitamin D3 replacement dosage will be increased to 2000 IU.

  Treatment: Vitamin D3

• Vitamin D non-deficiencyNo study treatment, for comparison

  No drug will be given to patients with Vitamin D non-deficiency.